Novartis (Symbol: NVS) has been named to the Dividend Channel ”International S.A.F.E. 10” list, signifying an international stock with above-average ”DividendRank”statistics including a strong 3.2% yield, as well as a superb track record of at least five years of dividend growth, according to the most recent ”DividendRank” report.
According to the ETF Finder at ETF Channel , Novartis is an underlying holding representing 1.45% of the Powershares International Dividend Achievers ETF ( PID ), which holds $12,345,394 worth of NVS shares. Novartis (Symbol: NVS) made the “Dividend Channel International S.A.F.E. 10” list because of these qualities: S . Solid return – hefty yield and strong DividendRank characteristics; A. Accelerating amount – consistent dividend increases over time; F . Flawless five year history – never a missed or lowered dividend; E. Enduring – at least a half-decade of dividend payments.
The annualized dividend paid by Novartis is $2.75/share, currently paid in annual installments, and its most recent dividend ex-date was on 03/01/2017.
NVS operates in the Drugs & Pharmaceuticals sector, among companies like Johnson & Johnson ( JNJ), and Pfizer Inc ( PFE ).
Source: Nasdaq
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
